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ABSTRACT: Protein arginine methyltransferase 1 (PRMT1)dependent methylation contributes to the onset and
progression of numerous diseases (e.g., cancer, heart disease,
ALS); however, the regulatory mechanisms that control
PRMT1 activity are relatively unexplored. We therefore set
out to decipher how phosphorylation regulates PRMT1
activity. Curated mass spectrometry data identiﬁed Tyr291, a
residue adjacent to the conserved THW loop, as being
phosphorylated. Natural and unnatural amino acid mutagenesis, including the incorporation of p-carboxymethyl-Lphenylalanine (pCmF) as a phosphotyrosine mimic, were used
to show that Tyr291 phosphorylation alters the substrate
speciﬁcity of PRMT1. Additionally, p-benzoyl-L-phenylalanine
(pBpF) was incorporated at the Tyr291 position, and crosslinking experiments with K562 cell extracts identiﬁed several
proteins (e.g., hnRNPA1 and hnRNP H3) that bind
speciﬁcally to this site. Moreover, we also demonstrate that Tyr291 phosphorylation impairs PRMT1’s ability to bind and
methylate both proteins. In total, these studies demonstrate that Tyr291 phosphorylation alters both PRMT1 substrate speciﬁcity
and protein−protein interactions.

P

conserved tyrosines (i.e., Tyr297, Tyr304, and Tyr307).
Phosphorylation of these residues, which is catalyzed by
constitutively active Janus kinase 2 (JAK2) mutants,6 inhibits
its association with MEP50, resulting in decreased PRMT5
activity.6
In contrast to PRMTs 4 and 5, no studies have shown that
phosphorylation alters PRMT1 activity. In fact, information on
how PTMs regulate PRMT1 activity is extremely limited. Given
that PRMT1 shows high in vitro activity, has the widest tissue
distribution and highest expression levels, and is thought to be
responsible for the generation of ∼85% of all the methylated
arginine residues found in vivo,10 this isozyme is likely subject to
multiple layers of regulation, including phosphorylation or
another PTM. Since PRMT1-dependent methylation contributes to the onset and progression of a range of diseases (e.g.,
cancer, heart disease, and ALS),1,2 a deeper understanding of its
regulation is required.

ost-translational modiﬁcations (PTMs) play a pivotal role
in the cell by adding additional regulatory layers. The
methylation of protein-embedded arginines is one example, and
this PTM regulates gene transcription, RNA splicing, and cell
proliferation.1,2 Arginine methylation is catalyzed by the protein
arginine methyltransferases (PRMT), which produce ωmonomethylarginine (ω-MMA) by transferring a methyl
group from S-adenosyl-methionine (SAM) to the guanidinium
moiety of an arginine. This modiﬁed residue can then be
further methylated to produce asymmetrically dimethylated
arginine (ADMA) or symmetrically dimethylated arginine
(SDMA).
Since arginine methylation regulates such a diverse array of
cellular processes, these enzymes must be regulated. In fact,
phosphorylation is known to control the activity of both
PRMT4 (CARM1)3−5 and PRMT5.6 For example, PRMT4 is
phosphorylated at Ser217, and this modiﬁcation diminishes its
methyltransferase activity in vitro and abrogates its coactivator
function in vivo.3 Ser217 phosphorylation likely disrupts an Hbond between the side chain hydroxyl and backbone carbonyl
of Tyr154, and as a result, the enzyme no longer binds
SAM.3,7−9 PRMT5 is also phosphorylated in vivo at three
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Figure 1. Structure of PRMT1. (A) Structure of PRMT1·SAH complex highlighting residues surrounding the THW loop. (B) Structures of tyrosine
and phosphotyrosine analogue used in these studies. This ﬁgure was prepared with UCSF Chimera using the coordinates from PRMT1 (PDB id
1ORI).

Figure 2. Incorporation of pCmF into the Y291TAG PRMT1 mutant and kinetic analysis of PRMT1 mutants. (A) Comparison of kinetic
parameters of PRMT1 and mutants with SAM, Histone H4, AcH4-21, and ERα-25. (B) Western blot analysis demonstrating the expression of the
full length protein, with the incorporation of pCmF at Y291, as well as the truncated form. (C) Coomasie-stained gel displaying the puriﬁed
Y291pCmF mutant. The yield was 1 mg/L of cell culture. Purity is estimated to be >90%.

introduction of a negatively charged phosphate group at
Tyr291 should introduce electrostatic repulsions that destabilize interactions between the Glu47-containing helix and the
THW loop (Figure 1). This hypothesis was based on previous
studies9 demonstrating that the stabilization of this helix (by a
salt bridge between His293 and Asp51) is important for
catalysis.9 Since no direct methods (e.g., site-directed mutagenesis) have been used to ascertain how Tyr291 phosphorylation regulates PRMT1 activity, we set out to determine its
function. Herein, we describe the results of these eﬀorts.

To address how phosphorylation regulates PRMT1 activity,
we used PhosphoSitePlus (www.phosphosite.org)11 to identify
several in vivo sites of PRMT1 phosphorylation. PhosphoSitePlus is a curated source of experimentally determined PTMs.11
From this database, we focused on Tyr291 phosphorylation
because this PTM is the most frequently identiﬁed, is present in
the conserved THW loop (see below), and is elevated in a
number of cancer cell lines (e.g., K-562, AMO-1, and KMS27).11 On the basis of the PRMT1 structure, we hypothesized
that phosphorylation would inhibit PRMT1 activity because the
650
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substrates and/or regulatory proteins that act to ﬁne-tune
PRMT1 cellular activity. Therefore, p-benzoyl-L-phenyl-alanine
(pBpF), a known photo-cross-linker,15,16 was incorporated
(Figure 3A and B) to facilitate the isolation of proteins that

RESULTS AND DISCUSSION
Kinetic Analysis of PRMT1 Phosphorylation Mutants.
To evaluate the importance of the Tyr291 hydroxyl group, we
ﬁrst generated the Y291F and Y291E mutants. Kinetic studies
revealed that neither mutation has a dramatic eﬀect on the
kinetic parameters for SAM, histone H4, as well as peptide
mimics of the histone H4 tail region (i.e., AcH4-21) or the site
of methylation in ERα (i.e., the ERα-25 peptide) (Figure 2A
and Supplementary Tables S1−S4). Because of the size and
electronic diﬀerences between glutamate and phosphotyrosine
(Figure 1), we used unnatural amino acid (UAA) mutagenesis
to install p-carboxymethyl-L-phenylalanine (pCmF) at this
position and thereby better mimic a phosphotyrosine.12 We
focused here on the use of unnatural amino acid mutagenesis to
install pCmF because the central location of Tyr291 in a highly
structured region of PRMT1 precluded the use of protein
semisynthetic methods to install a phosphonate analogue.13
To generate the Y291pCmF mutant, the Tyr291 codon was
mutated to TAG and pCmF was synthesized (Supplementary
Scheme S1) and incorporated using a previously evolved
orthogonal amber suppressor tRNA/aminoacyl-tRNA synthetase pair.12,14 Although both the full length protein (with pCmF
incorporated) and the truncated Y291TAG mutant are
expressed (Figure 2B), the truncated protein does not copurify with the Y291pCmF mutant (Figure 2C), likely due to
its inability to fold properly. Installation of pCmF was
conﬁrmed by tandem MS (Supplementary Figure S1 and
Table S5), and none of the amino acid substitutions aﬀected
protein stability, as measured by partial proteolysis experiments
(Supplementary Figure S2).
Similarly to the Y291F and Y291E mutants, the Y291pCmF
mutation showed limited eﬀects on the kinetic parameters for
SAM (Figure 2A and Supplementary Table S1). Given the
structure of PRMT1 and our previous studies showing that
destabilization of the N-terminal helix impacts SAM binding,
these results were somewhat surprising. To further investigate
the role of this modiﬁcation, we next determined the kinetic
parameters for histone H4 and found that the Y291pCmF
mutation shows only small eﬀects on kcat, KM, and kcat/KM; the
eﬀect is ≤2.4-fold (Figure 2A and Supplementary Supplementary Table S2). By contrast, we observed signiﬁcant eﬀects
on the kinetic parameters for methylation of the AcH4-21 and
ERα-25 peptides (Figure 2A and Supplementary Table S3−S4).
For example, with the AcH4-21 peptide, the Y291pCmF
mutant yielded a dramatic ∼11-fold decrease in kcat/KM
(Supplementary Table S3) with a comparable ∼10-fold
increase in KM. Similar results were obtained with ERα-25
(Supplementary Table S4). Although incorporation of pCmF
dramatically impacted kcat/KM, there was no eﬀect on the
processivity of the enzyme (Supplementary Figure S3). Despite
the lack of a large eﬀect with histone H4, which is likely due to
additional interactions between the core of H4 and PRMT1,
the results for the peptide substrates strongly argues in favor of
the notion that Tyr291 phosphorylation can modulate the
substrate speciﬁcity of PRMT1 in a substrate-speciﬁc manner.
Furthermore, the presence of a second negative charge, as
present in phosphotyrosine, would likely yield an even more
dramatic eﬀect.
Incorporation of pBpF, a Photo-Cross-Linking Amino
Acid. Given the variable eﬀects of methylating protein versus
peptide substrates, we also considered the possibility that
Tyr291 phosphorylation may act as part of a docking site for

Figure 3. Incorporation of pBpF into Y291TAG PRMT1 mutant and
cross-linking with histones. (A) Western blot analysis demonstrating
the expression of the full length protein, with the incorporation of
pBpF at Y291, as well as the truncated form. (B) Coomasie-stained gel
displaying the puriﬁed Y291pBpF mutant. The yield was 2 mg/L of
cell culture. Purity is estimated to be >90%. (Cc) Cross-linking of wild
type and the Y291pBpF mutant with histone H3 and H4.

interact with Tyr291. This substitution has only minor eﬀects
on the kinetic parameters for SAM, histone H4, and the AcH421 peptide (Supplementary Tables S1−S3). Interestingly,
however, there is a ∼10-fold decrease in kcat/KM for the ER25 peptide (Supplementary Table S4), further emphasizing that
modiﬁcations of this residue can ﬁne-tune the substrate
speciﬁcity of PRMT1.
Photo-Cross-Linking of the PRMT1(Y291pBpF) Mutant and Histones. To verify that Tyr291 plays a role in
substrate binding, we ﬁrst determined whether the Y291pBpF
mutant can cross-link with histone H4, a known substrate.
Histone H3, which is a relatively poorer PRMT1 substrate, was
used as a control (Figure 3C). As expected, histone H4, and to
a lesser extent histone H3, cross-link to the Y291pBpF mutant.
Interestingly, UV irradiation also induces a small amount of
cross-linking between the wild type enzyme and histone H4.
Although the source of this cross-linking is unknown, it may
relate to the presence of SAM, which is known to photo-crosslink to PRMT110 and other SAM-dependent methyltransferases.17
Photo-Cross-Linking and Co-immunoprecipitation of
K562 Extract Proteins with the PRMT1(Y291pBpF)
Mutant. Having demonstrated the UV-induced cross-linking
of Y291pBpF to a known substrate, we next identiﬁed
additional interacting proteins, reasoning they would be either
substrates or regulatory proteins that modulate the activity
and/or substrate speciﬁcity of PRMT1 in a phosphorylationdependent manner. Figure 4A represents a schematic depiction
of our approach. To ﬁrst determine the extent of cross-linking,
K562 cell extracts were incubated with PRMT1 or the
Y291pBpF mutant and subjected to UV irradiation. K562
cells were used because Tyr291 is phosphorylated in this
651
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from the gels and subjected to tryptic digestion followed by
MS/MS analysis. The results of two independent experiments
identiﬁed more than 75 proteins that co-immunoprecipitate
and/or cross-link to endogenous PRMT1, recombinant
PRMT1, and/or the Y291pBpF mutant (Supplementary
Table S6). Interestingly, the majority of these proteins are
involved in RNA processing and transcription, consistent with
the known cellular roles of PRMT1 (Figure 5 and
Supplementary Table S7). Importantly, a subset (∼25%) of
the proteins that cross-link with Y291pBpF are known
substrates (e.g., hnRNP A1 and hnRNP H3), conﬁrming a
role for this residue in modulating the substrate speciﬁcity of
PRMT1 (Figure 5 and Supplementary Tables S6−S7). The
remaining proteins either represent novel PRMT1 substrates or
interacting proteins that regulate PRMT1 activity, substrate
speciﬁcity, or subcellular localization.
To conﬁrm these interactions, the UV cross-linking experiments were repeated, and the blots were probed with either
anti-hnRNP A1 (Figure 4C) or anti-hnRNP H3 antibodies
(Supplementary Figure S4B). Gratifyingly, both hnRNP A1 and
hnRNP H3 cross-link with the Y291pBpF mutant. Further
validating these proteins as PRMT1 interacting proteins is the
fact that they also co-immunoprecipitate with PRMT1 and the
Y291pBpF mutant in the absence of UV. In total, these data
demonstrate that Tyr291 acts as a key point of contact between
PRMT1 and its substrates and/or interacting partners.
In Vitro Co-immunoprecipitation and Methylation of
hnRNP A1 and hnRNP H3 with the PRMT1(Y291pCmF)
Mutant. To evaluate whether Tyr291 phosphorylation alters
the interaction between hnRNP A1 and hnRNP H3, we
immunoprecipitated these proteins from K562 cell extracts and
then used them in an in vitro co-immunoprecipitation assay
with wild type PRMT1 and the Y291pCmF mutant. The results
of these studies (Figure 6A) indicate that, relative to wild type
PRMT1, signiﬁcantly smaller amounts of the Y291pCmF
mutant are co-immunoprecipitated by hnRNP A1 and, albeit to
a lesser extent, hnRNP H3. On the basis of these results, we
conclude that Tyr291 phosphorylation can inhibit interactions
between PRMT1 and both hnRNP A1 and hnRNP H3. To
follow up, we examined the eﬀect of Tyr291 phosphorylation
on the rates of hnRNP A1 and hnRNP H3 methylation.
Immunoprecipitated hnRNP A1 and hnRNP H3 were
incubated in the presence of 14C-labeled SAM and either
PRMT1 or the Y291pCmF mutant. The results show that both
hnRNP A1 and hnRNP H3 are poorly methylated by the
Y291pCmF mutant (Figure 6B), thereby demonstrating that
Tyr291 phosphorylation alters substrate recognition.

Figure 4. Cross-linking of the PRMT1(Y291pBpF) mutant with K562
cell extracts. (A) PRMT1 cross-linking schematic. (B) Wild type
PRMT1 or Y291pBpF mutant (10 μg) were incubated in the absence
or presence of K562 cell extracts (4.5 mg) followed by UV irradiation,
immunoprecipitation with anti-PRMT1, and Western blot analysis
with anti-PRMT1. Signiﬁcant cross-linking was observed at a high
molecular weight between the Y291pBpF mutant and proteins from
the K562 extracts. (C) The Y291pBpF mutant, but not wild type
PRMT1, cross-links with hnRNP A1.

myelogenous leukemia-derived cell line.11 Protein cross-linking
was then conﬁrmed by Western blotting. The results show a
signiﬁcant degree of cross-linking above 75 kDa for the UVtreated samples incubated with the Y291pBpF mutant (Figure
4B).
To identify these proteins and other PRMT1 interacting
proteins, the same procedure was used, except proteins >75
kDa (the approximate size of the PRMT1 dimer) were excised

Figure 5. Functions of identiﬁed proteins. (A) Functions of proteins that co-immunoprecipitate with both wild type PRMT1 and the Y291pBpF
mutant. The majority of the proteins are involved in RNA processing and transcription. (B) Functions of proteins that interact with and/or crosslink to only the Y291pBpF mutant.
652
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With regards to the cross-linking studies, the cellular
functions of the cross-linked proteins, as well as those proteins
that simply co-immunoprecipitated with PRMT1, coincide with
the known roles of PRMT1 in the cell. Interestingly, several
novel proteins were speciﬁcally recognized by Tyr291, thus
further suggesting that this residue is important for either
PRMT1 substrate speciﬁcity or regulating PRMT1 activity.
This conclusion is supported by the in vitro co-immunoprecipitation experiments, which clearly demonstrate that phosphorylation inhibits interactions between PRMT1 and hnRNP A1
and hnRNP H3. In addition, the methyltransferase activity of
the Y291pCmF mutant toward these two proteins was
signiﬁcantly decreased. In total, we show for the ﬁrst time
that phosphorylation of PRMT1 alters protein−protein
interactions and substrate speciﬁcity.

■

METHODS

Site-Directed Mutagenesis. PRMT1 mutants (i.e., Y291F,
Y291E, and Y291TAG) were generated using iProofHigh Fidelity
DNA Polymerase (Bio-Rad). The Y291F and Y291E mutant plasmids
were transformed into E. coli BL21(DE3) cells and puriﬁed according
to our already established protocol for wild type PRMT1.19 The
sequence of the Y291F, Y291E and Y291(TAG) mutagenic primers
(forward direction only) are 5′-CAGTCCTGAGTCTCCATTCACACATTGGAAGCAG-3′, 5′-CCAGTCCTGAGTCTCCAGAGACACATTGGAAGCAG-3′, and 5′-CCAGTCCTGAGTCTCCATAGACACATTGGAAGCAGAC-3′, respectively.
Incorporation of p-Carboxymethyl-L-phenylalanine (pCmF)
and p-Benzoyl-L-phenylalanine (pBpF). Unnatural amino acids
were incorporated using methods adapted from previously reported
protocols.12,14 Brieﬂy, the pEVOL-pCmF or pEVOL-pBpF plasmids
were cotransformed into E. coli C43(DE3) cells (Lucigen) with the
Y291TAG mutant. Single colonies was used to inoculate starter
cultures containing 50 μg/mL kanamycin and 25 μg/mL chloramphenicol in 2YT media, which were then used to start large scale
growths (1−2 L). These cells were grown at 37 °C and 200 rpm until
OD600 = 0.8 or 0.5 for the incorporation of pCmF and pBpF,
respectively. The cells were then supplemented with either 1 mM
pCmF or 250 μM pBpF, and protein expression was induced with
0.2% arabinose and isopropyl-β-D-thiogalactopyranoside (1 and 0.4
mM for the incorporation of pCmF and pBpF, respectively). The cells
were then incubated with shaking at 30 °C overnight, and the mutant
protein was puriﬁed according to a protocol already established for
wild type PRMT1.19
Cell Culture Maintenance and Whole Cell Extract Preparation. K562 cells were grown in Iscove’s Modiﬁed Dulbecco’s Medium
(IMDM) (ATCC) supplemented with 10% fetal bovine serum and 1%
antibiotic/antimycotic solution (Mediatech Inc.) at 37 °C and 5%
CO2. Cells were removed and centrifuged for 5 min at 225g and 4 °C.
After three washes with PBS, cells were resuspended in PBS (465 μL)
plus complete protease inhibitor cocktail (Roche 4693132) and
phosphatase inhibitor cocktail II (Sigma P8465) followed by 75 cycles
of sonication (1 s pulse with 10 s rest at 50% amplitude). Lysed cells
were centrifuged for 5 min at 3824g at 4 °C, and the supernatant was
removed as the whole cell extract. Protein concentration was
determined by a DC Protein Assay (Bio-Rad).
UV Cross-Linking with Histone H3 and H4. Wild type PRMT1
or the Y291pBpF mutant (0.5 μg) was incubated for 10 min on ice in
the absence and presence of histone H3 and H4 (1 μg) individually.
Samples were then subjected to 30 min of irradiation with UV light
(365 nm) on ice in a 96-well plate. Both the UV-treated samples and
control samples (non-UV-treated) were quenched with SDS-loading
dye and analyzed by Western blotting (see Supplementary Methods).
UV Cross-Linking and Immunoprecipitation with K562 Cell
Extracts. Wild type PRMT1 or the Y291pBpF mutant was incubated
for 10 min on ice in the absence and presence of K562 cell extracts
(4.5 mg) plus complete protease inhibitor cocktail (Roche-4693132).
Two independent experiments were performed, using either 45 or 10

Figure 6. In vitro co-immunoprecipitation and activity assay with
hnRNPs. (A) hnRNP A1 and hnRNP H3 were immunoprecipitated
from K562 cell extracts followed by incubation with either
recombinant wild type PRMT1 or the Y291pCmF mutant in an in
vitro co-immunoprecipitation assay. The samples were analyzed by
Western blotting. (B) Immunoprecipitated hnRNP A1 or hnRNP H3
were incubated in the presence of wild type PRMT1 or the
Y291pCmF mutant and 14C-labeled SAM followed by phosphorimage
analysis.

Conclusions. Taken together, these studies indicate that
Tyr291 phosphorylation alters both protein−protein interactions and the substrate speciﬁcity of PRMT1 in a substratedependent manner. Since PRMT1 splice variants primarily
diﬀer at the N-terminus of the protein and are also important
for substrate speciﬁcity,18 it is possible that phosphorylation of
Tyr291 will diﬀerentially modulate the substrate speciﬁcity of
these variants by altering the position of the N-terminal tail. It
is also possible that phosphorylation of this residue has a
greater eﬀect in vivo, in that the pCmF residue is still an
imperfect mimic of a phosphotyrosine as it diﬀers in both
charge and steric bulk. This notion is supported by the fact that
the pBpF mutation, although bulkier, did not induce a more
dramatic decrease in kcat/KM compared to the Y291pCmF
mutant. Also note that Tyr291 phosphorylation may also
modulate PRMT1 activity by providing a docking site for SH2
domain-containing proteins, which bind to phosphorylated
tyrosines. These issues will be addressed in follow up
experiments.
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μg of enzyme. PRMT1 samples, plus K562 cell extracts alone, were
then subjected to 30 min of irradiation with UV light (365 nm) on ice
in a 96-well plate. Both the UV-treated samples and control samples
(non-UV-treated) were incubated with rotation for 1 h with antiPRMT1 (Bethyl A300-722A) at 4 °C. Protein A/G Plus (sc-2003) (20
μL) was then added, and samples were incubated overnight at 4 °C
with rotation. Beads were collected by centrifugation at 1593g for 2
min and washed 3× with 200 μL of cold PBS. The supernatant was
removed, and 30 μL of 1× SDS-loading buﬀer was added followed by
heating at 95 °C for 10 min. Beads were collected by centrifugation at
1593g for 2 min, and the supernatant was removed and placed in a
new tube. Samples (15 μL) were then separated by 12% SDS-PAGE.
Additionally, 2-μL aliquots of the heated samples were removed
followed by the addition of 10 μL of 1× SDS-loading buﬀer to each to
be used for Western blot analysis. Proteins were identiﬁed by MS/MS
analysis (see Supplementary Methods for details).
In Vitro Co-immunoprecipitation with Wild Type and the
Y291pCmF Mutant. K562 cell extracts (4.5 mg) plus complete
protease inhibitor cocktail (Roche 4693132) were incubated with
rotation for 1 h with anti-hnRNP A1 (Santa Cruz sc-32301) or antihnRNP H3 (Santa Cruz sc-376416) antibodies at 4 °C. Protein A/G
Plus (sc-2003) (30 μL) was then added, and samples were incubated
overnight at 4 °C with rotation. Beads were collected by centrifugation
at 1593g for 2 min and washed 3× with 200 μL of cold PBS. Wild type
or the Y291pCmF mutant (10 μg) in cold PBS (250 μL ﬁnal volume)
was added, and samples were incubated with rotation for 1 h. Beads
were collected by centrifugation at 1593g for 2 min and washed 3×
with 200 μL of cold PBS. The supernatant was removed and 50 μL of
1× SDS-loading buﬀer was added followed by heating at 95 °C for 10
min. Beads were collected by centrifugation at 1593g for 2 min, and
the supernatant was removed and placed in a new tube. Samples (9
μL) were then separated by 12% SDS-PAGE and visualized by
Western blot analysis.
In Vitro Methylation of Immunoprecipitated hnRNPs. K562
cell extracts (6 mg) plus complete protease inhibitor cocktail (Roche
4693132) were incubated with rotation for 1 h with anti-hnRNP A1
(Santa Cruz sc-32301) or anti-hnRNP H3 (Santa Cruz sc-376416),
three separate samples per antibody, at 4 °C. Protein A/G Plus (sc2003) (30 μL) was then added, and samples were incubated overnight
at 4 °C with rotation. Beads were collected by centrifugation at 1593g
for 2 min and washed 3× with 200 μL of cold PBS. Beads were
incubated for 10 min at RT with 50 μL of 100 mM glycine-HCl pH
2.7 followed by centrifugation at 1593g for 2 min. The supernatant was
removed and neutralized with 5 μL of 1 M HEPES pH 8.2. Beads were
then incubated a second time for 10 min at RT with 50 μL of 100 mM
glycine-HCl pH 2.7 followed by centrifugation at 1593g for 2 min. The
supernatant was removed and combined with previous supernatant
and neutralized with 5 μL of 1 M HEPES pH 8.2. The supernatants
from three separate samples for each antibody were combined and
concentrated using Amicon Ultra-0.5 Centrifugal Filter Devices 10,000
NMWL (UFC501096) for 5 min at 16,000g. Utilizing the radioactive
based assay described above, reaction mixtures of 50 mM HEPES pH
8.0, 1 mM EDTA, 50 mM NaCl, 0.5 mM dithiothreitol, 15 μM [14C]labeled SAM, and 14 μL of immunoprecipitated hnRNP A1 or hnRNP
H3, 27 μL total reaction volume, were preincubated at 37 °C for 10
min. After the addition of 3 μL of 50 mM HEPES (Control), wild type
PRMT1 (2 μM), or the Y291pCmF mutant (2 μM), the reaction was
allowed to run for 1 h before being quenched with 6× SDS gel loading
buﬀer. Each assay was done in duplicate. Samples (15 μL) were
separated by 12% SDS-PAGE followed by visualization and
quantiﬁcation using phosphorimage analysis (Molecular Dynamics).
For Western blot input controls, 9 μL of concentrated immunoprecipitated hnRNP A1 and hnRNP H3, as well as 200 nM wild type
PRMT1 and the Y291pCmF mutant, was used and analyzed according
to the Western blot protocol described in the Supporting Information.
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Supplemental methods for the synthesis of p-carboxymethyl-Lphenylalanine (pCmF), in-gel digest and MS/MS analysis of
Y291pCmF mutant and UV cross-linking samples, puriﬁcation
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